Toll free: 1-855 542-5672 (1-855-KICK-MSA)


  1. Sun Z, Jia D, Shi Y, et al. Prediction of orthostatic hypotension in multiple system atrophy and Parkinson disease. Sci Rep. 2016;6:21649.
  2. Eschlböck, S., Wenning, G. & Fanciulli, A. Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. J Neural Transm124, 1567–1605 (2017).
  3. Palma JA, Norcliffe-Kaufmann L, Kaufmann H. An orthostatic hypotension mimic: The inebriation-like syndrome in Parkinson disease. Mov Disord. 2016;31(4):598–600.
  4. Tanaka K, et al. Compression stocking length effects on arterial blood pressure and heart rate following head-up tilt in healthy volunteers. Nursing Research. 2014;63(6):435–438.
  5. Barichella M, Pacchetti C, Bolliri C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT. Neurology. 2016; 87(12):1274–1280.
  6. Rembold CM. Coenzyme Q10 Supplementation in Orthostatic Hypotension and Multiple-System Atrophy: A Report on 7 Cases. Am J Med. 2018;131(4):444-446.
  7. Figueroa JJ, Basford JR, Low PA. Preventing and treating orthostatic hypotension: As easy as A, B, C. Cleve Clin J Med. 2010;77(5):298–306.
  8. Wieling, W., van, Dijk, N., Thijs, R.D., de, Lange, F.J., Krediet, C.T.P. and Halliwill, J.R. (2015), Physical countermeasures to increase orthostatic tolerance. J Intern Med, 277: 69-82.
  9. Grijalva CG, Biaggioni I, Griffin MR, Shibao CA. Fludrocortisone Is Associated With a Higher Risk of All-Cause Hospitalizations Compared With Midodrine in Patients With Orthostatic Hypotension. J Am Heart Assoc. 2017; 6(10).
  10. Parsaik AK, Singh B, Altayar O, et al. Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials. J Gen Intern Med. 2013;28(11):1496–1503.
  11. Pérez-Lloret S, et al. Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases, Expert Opinion on Pharmacotherapy. 2019;(20)6:635-645.
  12. Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension. Neurology. 2018;91(16):e1539–e1544.
  13. Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Archives of neurology. 2006; 63(4):513–518.
  14. Shibao C, Martinez J, Palma JA, Kaufmann H, Biaggioni I. Norepinephrine levels predicts the improvement in orthostatic symptoms after atomoxetine in patients with neurogenic orthostatic hypotension (P5.320). Neurology. 2017; 88(16 Supplement).
  15. Raccagni, C. et al. Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. Parkinsonism & Related Disorders. 2019; 67:60 – 65.
  16. Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson’s disease. N Engl J Med2012;366:511–519
  17. Meissner, Wassilios G. et al.Outcome of deep brain stimulation in slowly progressive multiple system atrophy: A clinico-pathological series and review of the literature. Parkinsonism & Related Disorders. 2016. 24:69 – 75.
  18. Wang L, Xiong N, Huang J, et al. Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson’s Disease. Front Aging Neurosci. 2017;9:206.
  19. Constantinescu, R., Richard, I. and Kurlan, R. Levodopa responsiveness in disorders with parkinsonism: A review of the literature. Mov. Disord. 2007. 22: 2141-2148.
  20. Friess, Elisabeth et al. Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. Parkinsonism & Related Disorders. 2006; 12(7):432 – 437.
  21. Boesch SM, Wenning GK, Ransmayr G, Poewe W. Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry. 2002;72(3):300–303.
  22. Dressler, D., Altenmueller, E., Bhidayasiri, R. et al.Strategies for treatment of dystonia. J Neural Transm 123, 251–258 (2016).
  23. Jain, S., Dawson, J., Quinn, N.P. and Playford, E.D. (2004), Occupational therapy in multiple system atrophy: A pilot randomized controlled trial. Mov. Disord., 19: 1360-1364.
  24. Müller, J., Wissel, J., Masuhr, F. et al.Clinical characteristics of the geste antagoniste in cervical dystonia. J Neurol 248, 478–482 (2001).
  25. Smania N, Corato E, Tinazzi M, Montagnana B, Fiaschi A, Aglioti SM. The effect of two different rehabilitation treatments in cervical dystonia: preliminary results in four patients. Funct Neurol 2003;18:219–225.
  26. Müller, J., Wenning, G., Wissel, J. et al.Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol 249, 300–304 (2002).
  27. Sakakibara R, Hattori T, Uchiyama T, et al. Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation?. J Neurol Neurosurg Psychiatry. 2000;68(1):65–69.
  28. Perez-Lloret S, Flabeau O, Fernagut PO, et al. Current Concepts in the Treatment of Multiple System Atrophy. Mov Disord Clin Pract. 2015;2(1):6–16.
  29. Yu Y, de Groat WC. Nitric oxide modulates bladder afferent nerve activity in the in vitro urinary bladder-pelvic nerve preparation from rats with cyclophosphamide induced cystitis. Brain Res. 2013;1490:83–94.
  30. St Louis EK, Boeve BF. REM Sleep Behavior Disorder: Diagnosis, Clinical Implications, and Future Directions. Mayo Clin Proc. 2017;92(11):1723–1736.
  31. Videnovic A. Management of sleep disorders in Parkinson’s disease and multiple system atrophy. Mov Disord. 2017;32(5):659–668.
  32. Du JJ, Wang T, Huang P, et al. Clinical characteristics and quality of life in Chinese patients with multiple system atrophy. Brain Behav. 2018;8(12):e01135.
  33. Segev-Jacubovski O, Herman T, Yogev-Seligmann G, Mirelman A, Giladi N, Hausdorff JM. The interplay between gait, falls and cognition: can cognitive therapy reduce fall risk?. Expert Rev Neurother. 2011;11(7):1057–1075.
  34. da Silva FC, Iop RDR, de Oliveira LC, et al. Effects of physical exercise programs on cognitive function in Parkinson’s disease patients: A systematic review of randomized controlled trials of the last 10 years. PLoS One. 2018;13(2):e0193113.
  35. Boggio, P.S., et al. (2005), Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson’s disease and concurrent depression. Mov. Disord., 20: 1178-1184.
  36. Cortelli P, Calandra-Buonaura G, Benarroch EE, et al. Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment. Neurology. 2019;93(14):630–639.
  37. Iranzo A. Sleep and breathing in multiple system atrophy. Curr Treat Options Neurol. 2007;9(5):347–353.
  38. Ghorayeb I, et al. Continuous positive airway pressure for sleep-related breathing disorders in multiple system atrophy: long-term acceptance. Sleep Medicine. 2005;6(4):359-362.
  39. Coon EA, Ahlskog JE, Silber MH, et al. Do selective serotonin reuptake inhibitors improve survival in multiple system atrophy?. Parkinsonism Relat Disord. 2018;48:51–53.
  40. You HY, Wu L, Yang HT, Yang C, Ding XL. A Comparison of Pain between Parkinson’s Disease and Multiple System Atrophy: A Clinical Cross-Sectional Survey. Pain Res Manag. 2019;2019:3150306.
  41. Pani G. Neuroprotective effects of dietary restriction: Evidence and mechanisms. Semin Cell Dev Biol. 2015;40:106-14.
  42. Alcalay, R.N., Gu, Y., Mejia‐Santana, H., Cote, L., Marder, K.S. and Scarmeas, N. (2012), The association between Mediterranean diet adherence and Parkinson’s disease. Mov. Disord., 27: 771-774.
  43. Maswood N, Young J, Tilmont E, et al. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson’s disease. Proc Natl Acad Sci U S A. 2004;101(52):18171–18176.
  44. Spinelli KJ, Osterberg VR, Meshul CK, Soumyanath A, Unni VK. Curcumin Treatment Improves Motor Behavior in α-Synuclein Transgenic Mice. PLoS One. 2015;10(6):e0128510.
  45. Molsberry, Samantha. 2019. Diet, Metabolomics, and Parkinson’s Disease. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences.
  46. Du, Juanjuan et al. Clinical correlates of decreased plasma coenzyme Q10 levels in patients with multiple system atrophy. Parkinsonism & Related Disorders. 2018;57:58 – 62.
  47. Kasai T, Tokuda T, Ohmichi T, et al. Serum Levels of Coenzyme Q10 in Patients with Multiple System Atrophy. PLoS One. 2016;11(1):e0147574.